Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 66.7%Moderate 1 · 33.3%High 0 · 0%

Hormone replacement therapy (HRT) vs no HRT

Progression‐free survival

Hormone replacement therapy (HRT) showed no clear difference in progression‐free survival compared with no HRT (low certainty).

1 finding from 1 review

Hormone replacement therapy after surgery for epithelial ovarian cancer 2020 · Cochrane Headline outcomes only
HR 0.76 [0.57, 1.01]
2 studies · 275 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Progression‐free survival · women with advanced or recurrent endometrial cancer

mTOR inhibitors may leads to higher progression‐free survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
HR 1.43 [1.06, 1.93]
1 study · 231 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Progression‐free survival: second/third‐line trials ( · women with advanced or recurrent endometrial cancer

mTOR inhibitors probably leads to lower progression‐free survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (moderate certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
HR 0.53 [0.31, 0.91]
1 study · 95 participants
Moderate